Vanishing bile duct syndrome and hodgkin disease: A case series and review of the literature

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 12, 2008, Pages 976-980

  Pass, Amy Kun ^a,c   McLin, Valerie A ^a   Rushton, Jennifer R ^a   Kearney, Debra L ^a   Hastings, Caroline A ^b   Margolin, Judith F ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Cholestasis; Hepatotoxicity; Hodgkin disease; Vanishing bile duct syndrome

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN G; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; MOPP ABV PROTOCOL; MOPP-ABV PROTOCOL; PROCARBAZINE;

ANAMNESIS; ARTICLE; BILE DUCT DISEASE; CANCER RADIOTHERAPY; CASE REPORT; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN G DEFICIENCY; LIVER BIOPSY; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SERODIAGNOSIS; TREATMENT RESPONSE; VANISHING BILE DUCT SYNDROME; CHOLESTASIS; MULTIMODALITY CANCER THERAPY; RADIATION DOSE; REMISSION; SYNDROME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHOLESTASIS; COMBINED MODALITY THERAPY; DOXORUBICIN; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; PREDNISONE; PROCARBAZINE; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SYNDROME; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 59149104999     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31818b37c4     Document Type: Article

References (24)

1. Yusuf MA, Elias E, Hubscher SG. Jaundice caused by the vanishing bile duct syndrome in a child with Hodgkin lymphoma. J Pediatr Hematol Oncol. 2000;22:154-157.
2. Ozkan A, Yoruk A, Celkan T, et al. The vanishing bile duct syndrome in a child with Hodgkin disease. Med Pediatr Oncol. 2001;36:398-399.
3. Gottrand F, Cullu F, Mazingue F, et al. Intrahepatic cholestasis related to vanishing bile duct syndrome in Hodgkin's disease. J Pediatr Gastroenterol Nutr. 1997;24:430-433.
4. Komurcu S, Ozet A, Altundag MK, et al. Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin's disease. Ann Hematol. 2002;81:57-58.
5. Strazzabosco M, Spirli C, Okolicsanyi L. Pathophysiology of the intrahepatic biliary epithelium. J Gastroenterol Hepatol. 2000;15: 244-253.
6. Hubscher SG, Lumley MA, Elias E. Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology. 1993;17:70-77.
7. Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol. 1995;13: 1080-1088.
8. Hubscher SG, Buckels JA, Elias E, et al. Reversible vanishing bile duct syndrome after liver transplantation: report of 6 cases. Transplant Proc. 1991;23(1 Pt 2):1415-1416.
9. Taghian M, Tran TA, Bresson-Hadni S, et al. Acute vanishing bile duct syndrome after ibuprofen therapy in a child. J Pediatr. 2004; 145:273-276.
10. Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol. 1996; 91:1626-1630.
11. de Galoscy C, Horsmans Y, Rahier J, et al. Vanishing bile duct syndrome occurring after carbamazepine administration: a second case report. J Clin Gastroenterol. 1994;19:269-271.
12. Moradpour D, Altorfer J, Flury R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology. 1994;20:1437-1441.
13. Altraif I, Lilly L, Wanless IR, et al. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. Am J Gastroenterol. 1994;89:1230-1234.
14. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangio-pathies. J Clin Gastroenterol. 2005;39(suppl 2):S90-S102.
15. Vierling JM, Howell CD. Disappearing bile ducts: immunologic mechanisms. Hosp Pract (Off Ed). 1990;25:141-150.
16. Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis. 1993;13:261-275.
17. Bouroncle BA, Old JW Jr, Vazques AG. Pathogenesis of jaundice in Hodgkin's disease. Arch Intern Med. 1962;110:872-883.
18. Liangpunsakul S, Kwo P, Koukoulis GK. Hodgkin's disease presenting as cholestatic hepatitis with prominent ductal injury. Eur J Gastroenterol Hepatol. 2002;14:323-327.
19. Crosbie OM, Crown JP, Nolan NP, et al. Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease. Hepatology. 1997;26:5-8.
20. Barta SK, Yahalom J, Shia J, et al. Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. Clin Lymphoma Myeloma. 2006;7:77-82.
21. Rossini MS, Lorand-Metze I, Oliveira GB, et al. Vanishing bile duct syndrome in Hodgkin's disease: case report. Sao Paulo Med J. 2000;118:154-157.
22. Jalbout M, Bel Hadj Jrad B, Bouaouina N, et al. Autoantibodies to tubulin are specifically associated with the young age onset of the nasopharyngeal carcinoma. Int J Cancer. 2002;101:146-150.
23. Kikuchi K, Miyakawa H, Abe K, et al. Vanishing bile duct syndrome associated with chronic EBV infection. Dig Dis Sci. 2000;45:160-165.
24. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200:1623-1633.